Skip to main content
CADL
NASDAQ Life Sciences

Candel Posts Q2 Loss, Holds $201.6M Cash, Targets Q4 BLA Filing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$10.56
Mkt Cap
$782.526M
52W Low
$4.35
52W High
$11.36
52W Position info
143% above low
Off High info
7.0% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CADL has more than doubled off its 52-week low of $4.35.

Summary

Candel Therapeutics posted a Q2 net loss of $38.9 million and ended the quarter with $201.6 million in cash, enough to fund operations into Q1 2028. The company plans to submit a BLA for its lead prostate cancer therapy in Q4 2026.


Key Events · Earnings and Guidance · CADL

  • Q2 Net Loss Widens

    Net loss was $38.9 million for Q2 2026, compared to $4.8 million in Q2 2025, driven by higher R&D spending and a $12.3 million non-cash warrant liability charge.

  • Cash Runway Extended

    Cash and cash equivalents totaled $201.6 million as of June 30, 2026, up from $119.7 million at year-end 2025, expected to fund operations into Q1 2028.

  • BLA Submission Planned

    Company plans to submit a Biologics License Application for aglatimagene in localized prostate cancer in Q4 2026, with potential U.S. launch in 2027 if approved.

  • Commercial Readiness

    Appointed Mark Sims as Chief Commercial Officer in June 2026 and announced a commercialization agreement with EVERSANA to support a potential launch.


Analysis · CADL · Life Sciences

A wider Q2 net loss of $38.9 million reflects higher R&D spending and a $12.3 million non-cash warrant liability charge. With $201.6 million in cash at quarter-end, the runway extends into Q1 2028. Management reiterated plans to submit a BLA for aglatimagene in prostate cancer in Q4 2026, a key regulatory milestone that could support a 2027 launch.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CADL was trading at $10.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $782.5M. The 52-week trading range was $4.35 to $11.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $5.04 info
Change: -$0.0703 (-1%) info
Market Cap: $395.368M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $5.04 info
Change: -$3.35 (-40%) info
Market Cap: $395.368M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $5.04 info
Change: -$3.35 (-40%) info
Market Cap: $395.368M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $5.04 info
Change: -$5.36 (-52%) info
Market Cap: $395.368M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $5.04 info
Change: -$5.92 (-54%) info
Market Cap: $395.368M info